Open Access. Powered by Scholars. Published by Universities.®
Immunoprophylaxis and Therapy Commons™
Open Access. Powered by Scholars. Published by Universities.®
- Discipline
-
- Allergy and Immunology (2)
- Biochemistry (2)
- Biochemistry, Biophysics, and Structural Biology (2)
- Biological Engineering (2)
- Biological Phenomena, Cell Phenomena, and Immunity (2)
-
- Biomedical Engineering and Bioengineering (2)
- Cancer Biology (2)
- Cell and Developmental Biology (2)
- Disease Modeling (2)
- Engineering (2)
- Genetics (2)
- Genetics and Genomics (2)
- Immunity (2)
- Medical Immunology (2)
- Medical Sciences (2)
- Medical Specialties (2)
- Neoplasms (2)
- Oncology (2)
- Translational Medical Research (1)
- Publication
- Publication Type
Articles 1 - 3 of 3
Full-Text Articles in Immunoprophylaxis and Therapy
Modeling The Adaptive Immune Response To Mutation-Generated Antigens, Rory J. Geyer
Modeling The Adaptive Immune Response To Mutation-Generated Antigens, Rory J. Geyer
University Scholar Projects
Somatic mutations may drive tumorigenesis or lead to new, immunogenic epitopes (neoantigens). The immune system is thought to represses neoplastic growths through the recognition of neoantigens presented only by tumor cells. To study mutations as well as the immune response to mutation-generated antigens, we have created a conditional knockin mouse line with a gene encoding, 5’ to 3’, yellow fluorescent protein (YFP), ovalbumin (which is processed to the immunologically recognizable peptide, SIINFEKL), and cyan fluorescent protein (CFP), or, YFP-ovalbumin-CFP. A frame shift mutation has been created at the 5’ end of the ovalbumin gene, hence YFP should always be expressed, …
Modeling The Adaptive Immune Response To Mutation-Generated Antigens, Rory J. Geyer
Modeling The Adaptive Immune Response To Mutation-Generated Antigens, Rory J. Geyer
Honors Scholar Theses
Somatic mutations may drive tumorigenesis or lead to new, immunogenic epitopes (neoantigens). The immune system is thought to represses neoplastic growths through the recognition of neoantigens presented only by tumor cells. To study mutations as well as the immune response to mutation-generated antigens, we have created a conditional knockin mouse line with a gene encoding, 5’ to 3’, yellow fluorescent protein (YFP), ovalbumin (which is processed to the immunologically recognizable peptide, SIINFEKL), and cyan fluorescent protein (CFP), or, YFP-ovalbumin-CFP. A frame shift mutation has been created at the 5’ end of the ovalbumin gene, hence YFP should always be expressed, …
Cancer Immunotherapy Treatments, Shifra Sadowsky
Cancer Immunotherapy Treatments, Shifra Sadowsky
The Science Journal of the Lander College of Arts and Sciences
Cancer is the second leading cause of death in American, with over half a million deaths from cancer reported in 2009. Cancer chemotherapy treatments were developed in the nineteen hundreds and remain the backbone of current treatments; however, they have some limitations. New immunotherapy cancer treatments, where biologic agents are given to patients to influence the body’s natural immune response, are being researched. Among these immunotherapy treatments are co-inhibition blockade of T cells, and combination blockade treatments together with chemotherapy treatment. This review will discuss T cell activation and the role of T cell coinhibitors such as CTLA-4 and PD-1 …